Thermo Fisher Scientific Q3 2026 Earnings: Organic Growth Accelerates as Pharma Services and Instruments Lead

Thermo Fisher Scientific reported third-quarter revenue of $12.14B, up 9% year over year, including 6% organic growth. GAAP diluted EPS increased 9% to $4.64, while adjusted EPS rose 15% to $6.68. The quarter showed a broad improvement in customer activity, particularly in pharma and biotech, semiconductor-related analytical instruments, and China, although part of the earnings outperformance reflected a one-time tariff-refund recovery.

Earnings Snapshot

The Bigger Story

Thermo Fisher’s third quarter provided further evidence that its core end markets are recovering from the slower demand environment of the past several years. Organic growth accelerated to 6% from 3% in the first half, with management pointing to improved activity across pharma and biotech, industrial applications, and Asia Pacific.

The improvement was not evenly distributed. Laboratory Products and Biopharma Services, which includes Pharma Services and clinical research, produced 10% organic growth. Analytical Instruments also posted 6% organic growth, supported by electron microscopy demand tied to semiconductor applications.

The more important question is whether this momentum can become durable and broad-based. Management maintained a 4% organic-growth outlook for the fourth quarter, partly because Pharma Services activity was weighted toward the third quarter. Meanwhile, Life Sciences Solutions grew just 1% organically, suggesting that demand for research reagents has not yet recovered at the same pace as clinical development and laboratory channel activity.

Revenue and Operating Performance

Reported revenue increased 9% to $12.14B. Acquisitions added 4 percentage points of growth, while the completed divestiture of the microbiology business reduced reported growth by 1 percentage point. Currency had no net impact on quarterly revenue growth.

Organic growth was led by the Laboratory Products and Biopharma Services segment, where revenue rose 15% to $6.86B and organic growth reached 10%. Management cited strong growth in Pharma Services, the research and safety market channel, and clinical research. The company said the strength in Pharma Services was partly related to the timing of customer activity, with a greater portion of expected second-half work completed in the third quarter.

Life Sciences Solutions revenue increased 5% to $2.72B, but organic growth was only 1%. Bioproduction was the segment’s strongest contributor, although management said its growth rate moderated relative to recent quarters because of more difficult comparisons. Demand for bioscience and genetic-science reagents remained comparatively muted, though management expects improving biotech conditions to eventually support those businesses.

Analytical Instruments generated revenue of $2.00B, up 6% on both a reported and organic basis. Electron microscopy was the primary growth driver, aided by demand from semiconductor research, quality control, and manufacturing ramp activity. Chromatography and mass spectrometry also contributed.

Specialty Diagnostics revenue declined 6% to $1.10B, though organic revenue was flat. The microbiology divestiture weighed on reported results. Transplant diagnostics grew, but that was not enough to produce organic segment growth.

Geographically, management said North America and Europe grew at mid-single-digit rates, while Asia Pacific grew in the low double digits. China also grew in the low double digits, driven primarily by pharma, biotech, and industrial and applied markets.

Profitability and Margins

Adjusted operating income increased 15% to $2.97B, and adjusted operating margin expanded 120 basis points to 24.5%. GAAP operating income rose 17% to $2.26B, with GAAP operating margin also up 120 basis points to 18.6%.

The margin expansion reflected productivity gains and favorable volume leverage. These benefits offset unfavorable business mix and supported continued investment in product development, capacity, AI deployment, and employees.

Analytical Instruments produced the strongest segment-level margin improvement. Segment income increased 26% to $538M, and segment margin expanded 430 basis points to 26.9%. Management attributed the improvement to productivity, volume leverage, and favorable mix, partly offset by strategic investments.

Laboratory Products and Biopharma Services segment income rose 23% to $1.07B, with margin up 100 basis points to 15.5%. The Clario acquisition contributed to profit growth, while unfavorable mix and strategic investments limited some of the margin benefit.

Specialty Diagnostics segment margin improved 360 basis points to 31.0%, despite flat organic revenue, while Life Sciences Solutions margin increased 20 basis points to 37.6%.

Adjusted EPS of $6.68 was $0.26 above the company’s prior outlook. Management said $0.08 of that outperformance came from operational execution and higher revenue, $0.03 from foreign exchange, and $0.15 from tariff refunds recognized during the quarter.

The tariff-related benefit is important to separate from recurring performance. Thermo Fisher recognized roughly $60M of adjusted operating income, or 50 basis points of adjusted margin, from approved refund claims. Management also reinvested part of the recovery into AI deployment, Pharma Services capacity, and employee-related initiatives.

GAAP and adjusted results remain meaningfully different due largely to acquisition-related intangible amortization. The quarter included $519M of such amortization, as well as $199M in restructuring and other costs. The restructuring category included a $72M gain on the sale of a business and a $244M held-for-sale loss.

Demand, Customers and Pricing

Management characterized end-market conditions as stronger than in the first half. Pharma and biotech grew at a high-single-digit rate, supported by Pharma Services, clinical research, and laboratory channel activity. Management said biotech customer confidence has improved alongside better funding conditions and greater optimism around development pipelines.

The company expects recovery in biotech spending to unfold in stages. Clinical research and laboratory-channel demand improved first, while high-value research reagents remain earlier in their recovery. Management expects research customers to increase spending on those technologies over the next several quarters if current conditions persist.

Academic and government revenue was flat. Demand for high-end analytical instruments, including chromatography, mass spectrometry, and electron microscopy, remained solid, but it did not translate into broader end-market growth.

Thermo Fisher also highlighted ongoing demand tied to semiconductor applications. Its electron microscopy platforms are used in semiconductor research and manufacturing processes, and management said the business benefited from strong customer activity during the quarter.

The company continues to position AI as both a customer-demand driver and an internal productivity tool. Management described AI-enabled workflows in electron microscopy, clinical research, and laboratory automation. The economic argument is that improved research productivity and higher drug-development returns could lead customers to invest more in instruments, consumables, and outsourced services. However, management did not quantify AI’s revenue contribution or provide a timeline for a material company-wide growth benefit.

What is Thermo Fisher Scientific’s guidance for full-year 2026?

Thermo Fisher raised its full-year 2026 outlook following the third-quarter outperformance.

Management now expects:

• ·Revenue of $47.7B to $48.2B, representing reported growth of 7% to 8% over 2025.
• ·Organic revenue growth of 4% for the full year.
• ·Adjusted EPS of $25.13 to $25.43, representing growth of 10% to 11%.
• ·Adjusted operating margin expansion of 80 basis points for the year.
• ·Free cash flow of $7B to $7.5B.
• ·Net capital expenditures of $1.9B to $2B.
• ·Net interest expense of approximately $650M.
• ·An adjusted tax rate of 11.5%.
• ·Average diluted shares of 371 million to 372 million.

For the fourth quarter, management maintained its expectation for 4% organic revenue growth. The company said the sequential moderation from 6% organic growth in the third quarter reflects the timing of Pharma Services customer activity rather than a deterioration in underlying commercial momentum.

At the midpoint, the full-year adjusted EPS outlook increased by $0.15. Management attributed $0.09 to operational performance, $0.05 to the net tariff-refund benefit after approximately $40M of incremental fourth-quarter reinvestment, and $0.01 to foreign exchange.

Balance Sheet, Cash Flow and Capital

Thermo Fisher generated $5.87B of operating cash flow and $4.62B of free cash flow through the first nine months of 2026, compared with $4.36B and $3.32B, respectively, in the prior-year period. The improvement reflects higher earnings and working-capital performance, partly offset by higher capital expenditures.

The company invested $1.26B in capital expenditures through September. It also spent $8.88B on acquisitions, net of acquired cash, during the first nine months, while receiving $1.02B of proceeds from the microbiology divestiture.

At quarter-end, Thermo Fisher held $6.1B of cash and short-term investments and had $41.4B of total debt. Gross leverage was 3.4 times adjusted EBITDA, while net leverage was 2.9 times.

Capital returns remained substantial. The company repurchased $4B of stock through the first nine months and paid $511M in dividends. Management’s full-year assumptions include $4B of repurchases and roughly $700M of dividends.

What Investors Should Watch

1. Whether Pharma Services growth remains durable

Pharma Services was the largest contributor to third-quarter outperformance, but management said some customer activity shifted into the third quarter. Investors should watch whether fourth-quarter results support the company’s view that the business retains strong commercial momentum rather than merely benefiting from timing.

2. A broader biotech recovery

Clinical research and laboratory channel demand have improved, but Life Sciences Solutions organic growth was only 1%. A sustained recovery in research reagents, genetic sciences, and bioscience products would provide stronger evidence that biotech spending is broadening.

3. Analytical Instruments demand in semiconductors and China

Electron microscopy demand supported both revenue growth and margin expansion in Analytical Instruments. Continued growth in semiconductor-related applications and China would help validate that this was not a one-quarter delivery concentration.

4. Margin performance excluding tariff refunds

The tariff-refund recovery added approximately 50 basis points to third-quarter adjusted operating margin. Thermo Fisher’s ability to sustain its full-year 80-basis-point margin-expansion target after this one-time benefit will be an important test of underlying productivity and volume leverage.

5. Acquisition execution and leverage

The company is integrating Clario and its filtration and separation business while carrying $41.4B of total debt. Management said both acquired businesses are performing well, but investors should monitor revenue synergies, capacity investments, free-cash-flow conversion, and progress toward lower leverage.

AlgovestIQ Takeaway

Thermo Fisher’s third quarter was stronger than the headline 9% revenue growth alone suggests. Organic growth accelerated to 6%, key end markets improved, and the company delivered broad margin expansion despite continued investments in innovation, AI, and capacity.

The most encouraging operating development was the strength in Pharma Services, clinical research, laboratory channels, and semiconductor-related analytical instruments. Those areas indicate that customers are again increasing activity in development, manufacturing, and advanced research workflows. Low-double-digit growth in China also marked a constructive change in regional momentum.

Still, the recovery is incomplete. Academic and government demand remained flat, Specialty Diagnostics was flat organically, and Life Sciences Solutions grew only 1% organically. The company’s core reagent businesses have yet to show the same degree of recovery seen in services, channels, and instruments.

The one-time tariff-refund benefit also deserves attention. It helped third-quarter adjusted EPS by $0.15 and adjusted operating income by roughly $60M, even after targeted reinvestment. Thermo Fisher’s raised outlook reflects genuine operating improvement, but the quarterly earnings beat should not be viewed as entirely recurring.

The central investment question is whether improving customer confidence can translate into sustained mid-single-digit organic growth across more of the portfolio. Evidence of a broader biotech reagent recovery, continued Pharma Services momentum, and margin resilience without one-time benefits would strengthen that case. A sharper-than-expected fourth-quarter slowdown in Pharma Services or continued weakness in Life Sciences Solutions would temper it.